Manatt Health February 17, 2025
Julian Polaris, Blair Cantfil, Alexander Dworkowitz, Julie A. Eller

Below is an excerpt from a recent Manatt Health white paper. Click here to read the full report.

Thanks to breakthroughs in precision medicine, leading scientists have developed a growing number of cell and gene therapies (CGTs) for serious and life-threatening diseases. By addressing the root causes of disease, these transformative therapies can slow, stop, or even reverse disease progression, achieving life-changing results for patients who previously had no hope of effective treatment.

Troublingly, these breakthroughs are not accessible to all. Nationwide, the low-income people covered by the Medicaid program have reduced access to CGTs compared to those covered by Medicare or commercial insurance. On paper, federal law provides that all Medicaid enrollees should have timely access to Food and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Medicaid, Patient / Consumer, Pharma / Biotech, Provider
Related Articles:
FDA approves first rapid-acting insulin biosimilar for diabetes
Pharma Pulse 2/20/25: Popping the Gross-to-Net Bubble, Prompting Better Care with Question Prompt Lists & more
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall

Share This Article